Interfacial inhibition of macromolecular interactions: nature's paradigm for drug discovery
- 1 March 2005
- journal article
- review article
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 26 (3) , 138-145
- https://doi.org/10.1016/j.tips.2005.01.008
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- Structures of Three Classes of Anticancer Agents Bound to the Human Topoisomerase I−DNA Covalent ComplexJournal of Medicinal Chemistry, 2005
- Mechanisms of Camptothecin Resistance by Human Topoisomerase I MutationsJournal of Molecular Biology, 2004
- Small-molecule inhibitors of protein–protein interactions: progressing towards the dreamNature Reviews Drug Discovery, 2004
- Structural snapshots of the mechanism and inhibition of a guanine nucleotide exchange factorNature, 2003
- The mechanism of topoisomerase I poisoning by a camptothecin analogProceedings of the National Academy of Sciences, 2002
- Small-molecule inhibitors of cell signalingCurrent Opinion in Biotechnology, 2000
- Binding site of brefeldin A at the interface between the small G protein ADP-ribosylation factor 1 (ARF1) and the nucleotide-exchange factor Sec7 domainProceedings of the National Academy of Sciences, 2000
- Topoisomerase I inhibitors: selectivity and cellular resistanceDrug Resistance Updates, 1999
- Anatomy of hot spots in protein interfacesJournal of Molecular Biology, 1998
- Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicinNucleic Acids Research, 1990